Compare ResMed Inc. (RMD) vs TORM plc (TRMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs TORM plc — how do they compare? ResMed Inc. trades at $219.5 (market cap $31.73B), while TORM plc trades at $33.8 (market cap $3.43B). The key difference: ResMed Inc. is far larger — about 9.3× TORM plc's market cap, and TORM plc pays the higher dividend (12.47%). Which is the better fit depends on your goals.
| RMD | TRMD | |
|---|---|---|
Market Cap | $31.73B | $3.43B |
Sector | Health | Technology |
52-Week High | $283.28 | $35.46 |
52-Week Low | $182.82 | $19.39 |
Enterprise Value | $31.08B | $4.14B |
Dividend Yield | 1.2% | 12.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $221.05, down 3.2% on the day, with a bearish technical signal and key support at $218. The company reported strong Q4 2026 results, beating EPS estimates at $2.95, and maintains robust profitability with a 26.94% net income margin. Revenue growth remains solid, reaching $5.15B in 2025, though weak 2027 sales guidance has pressured the stock. A dividend of $0.66 is scheduled for payment in September 2026.
Outlook is mixed: strong fundamentals and a consensus price target of $235.70 suggest upside, but bearish technicals and investor lawsuits pose near-term risks. The stock offers value with a P/E of 21.19, yet competitive and regulatory challenges require monitoring for sustained growth.
TRMD trades at $34.94, down 0.68% today, with a bullish technical signal from moving averages and strong support at $34. The company reported record Q2 2026 earnings with $3.25 EPS, though slightly missing estimates, and maintains robust profitability with a 35.52% net margin. Recent news highlights a capital increase from RSU exercises and a strong dividend of $2.40 payable in September 2026.
Outlook is positive with 100% analyst buy ratings, underpinned by strong cash flow growth and high ROE of 26.84%. Risks include reliance on volatile freight rates and potential market corrections given elevated RSI levels. The stock presents value with a low P/E of 5.75, but investors should monitor earnings consistency and global trade dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →
